⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Riassunto: I risultati dello studio clinico pivotale di Fase 3 frontMIND di Incyte sulla combinazione di Tafasitamab (Monjuvi®/Minjuvi®) presentati in occasione della sessione plenaria del congresso 2026 della European Hematology Association (EHA)...
businesswire.com
INCY
Resumen: Los resultados del ensayo fundamental frontMIND fase 3 de la combinación tafasitamab (Monjuvi®/Minjuvi®) de Incyte presentados en el plenario del Congreso de la Asociación Europea de Hematología (EHA) 2026...
businesswire.com
INCY
Les résultats de l’essai pivot de phase 3 frontMIND mené par Incyte sur l’association thérapeutique à base de tafasitamab (Monjuvi®/Minjuvi®), présentés lors de la séance plénière du congrès 2026 de l’Association européenne d’hématologie (EHA)...
businesswire.com
INCY
Ergebnisse der zulassungsrelevanten Phase-3-Studie „frontMIND“ von Incyte zur Kombination von Tafasitamab (Monjuvi® /Minjuvi® ), die auf der Plenarsitzung des Kongresses der European Hematology Association (EHA) 2026 vorgestellt wurden...
businesswire.com
INCY
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
businesswire.com
INCY
MIRM
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
businesswire.com
INCY
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
businesswire.com
INCY
Form 8-K
sec.gov
INCY
Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
RAPT
SANG
INCY
ABBV
ARCT
AMGN
CHKP
PFE
LLY
SCLX
SNY
UCB
BIIB
NVS
VTRS
BMY
ABSI
ALEC
GSK
IONS
CLNN
ANNX
MED
GAM
VRTX
EXC
BLRX
Form 8-K
sec.gov
INCY